Novo Nordisk Prices Its Plan B
Novo Nordisk has just announced a multi-month subscription program for Wegovy, its FDA-approved obesity treatment, offering savings of up to $1,200 annually for out-of-pocket patients in the United States. The news circulated simultaneously in WSJ, CNBC, Reuters, and Axios in recent days, which is no coincidence: the Danish company needs to regain ground against Eli Lilly and a wave of telemedicine competitors already operating with more flexible pricing structures.
The mechanism is straightforward: instead of selling individual doses at the list price, Novo is offering a multi-month commitment at a reduced rate. For the uninsured or underinsured patient, the promise is concrete. For Novo Nordisk, the gamble is that this multi-month commitment will generate retention, predictable income, and, above all, information on who is actually paying and at what price.
The Subscription Model as a Gauge of Willingness to Pay
The first thing to understand is that this program is neither philanthropy nor just a discount tactic. It is the first structured mechanism that Novo Nordisk is deploying to measure how many real patients, outside the insurance system, are willing to financially commit to a chronic treatment.
Here’s the important data: obesity as a chronic condition requires prolonged adherence. A drug like Wegovy won’t work if the patient abandons it after three months due to unaffordable costs. Until now, Novo primarily sold through insurers and health systems, where the real price is obscured by institutional negotiations. With the direct-to-consumer subscription program, the company is, for the first time, facing the equation directly: this price, this commitment, this dropout rate.
This is market information that no consulting firm study can replace. And Novo was obtaining it too slowly while Eli Lilly and telemedicine platforms were already operating more nimbly in the direct payment segment. The market did not wait.
What makes this move analytically interesting is its implicit financial architecture. By converting a transactional sale into a multi-month commitment, Novo transforms variable revenue into more predictable streams, which improves quarterly financial visibility and reduces exposure to the volatility of insurance coverage decisions. This is a crucial detail for a company whose stock has faced significant pressure in recent months precisely due to doubts about the actual penetration of the self-funded market.
Why It Came Late and What It Says About Internal Decision-Making Processes
The competitive context is uncomfortable for Novo Nordisk. Eli Lilly has been gaining ground for months with Zepbound, and telemedicine platforms that offer compounded semaglutide at significantly lower prices have captured a market share that Novo never measured with sufficient urgency. The subscription program arrives at a time when the accessibility issue had already generated alternative solutions in the market, some of them regulatory gray areas.
This reveals an organizational pattern worth naming plainly: large pharmaceutical companies tend to build their access model around the insurance system and then try to adapt that model to the direct market only when competitive pressure becomes evident. The result is that learning about the direct pay customer lags behind more agile competitors. Novo is no exception to this logic; it stands as its most visible example this season.
The operational question that this subscription must answer in the next two or three quarters is specific: at what price and under what commitment structure will the uninsured patient complete treatment without abandoning it? This is not something any financial model created in a conference room in Copenhagen can know. Real adherence data knows, and that data is only generated when there is a visible price and a signed commitment.
The program's non-trivial risk is that it primarily attracts patients who were already in the system and are looking to pay less, rather than expanding the market to those who currently cannot access Wegovy due to price. If the subscription cannibalizes revenue from existing patients without incorporating new ones, the net result is a deterioration of average revenue per user without a gain in volume. That scenario is not unlikely, and Novo will need to monitor the composition of new users with the same attention as the gross number of subscribers.
The Visible Price is the Experiment That Matters
Beyond Novo Nordisk and the specific battle for the GLP-1 market, this move illustrates something that companies with chronic health products learn painfully late: putting a visible price on a product and demanding a concrete commitment is the only way to obtain reliable market signals.
Companies that operate solely through institutional intermediaries, whether insurers, hospital systems, or distribution pharmaceuticals, have a structural information problem. They know the price negotiated by the system, but they do not know what the end user would do if they had to choose and pay directly. That information gap is costly when a competitor shows up willing to close it faster.
What Novo is doing with this subscription, even if it may not articulate it in those terms, is rapidly closing that gap. The discount of up to $1,200 annually is not just an incentive for the patient; it's the cost that Novo incurs to obtain real payment behavior data they previously did not have. Viewed this way, the investment has a logic that goes beyond marketing.
The outcome of this experiment will determine whether Novo can build a sustainable direct channel or if it will end up depending indefinitely on institutional coverage for its most strategic product. That answer will come in the next few quarters, not in any forecast.
Leaders observing this case from other industries have an immediately applicable lesson: the only business plan that generates certainty is not the one with the most pages or the one projecting the most scenarios, but the one that puts a price in front of a real customer and records what happens. Everything else is theory that the market will end up correcting anyway.
